Cargando…
Development of iPSC-based clinical trial selection platform for patients with ultrarare diseases
A “Leap-of-Faith” approach is used to treat patients with previously unknown ultrarare pathogenic mutations, often based on evidence from patients having dissimilar but more prevalent mutations. This uncertainty reflects the need to develop personalized prescreening platforms for these patients to a...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Association for the Advancement of Science
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8993122/ https://www.ncbi.nlm.nih.gov/pubmed/35394834 http://dx.doi.org/10.1126/sciadv.abl4370 |
_version_ | 1784683849727344640 |
---|---|
author | Sequiera, Glen Lester Srivastava, Abhay Sareen, Niketa Yan, Weiang Alagarsamy, Keshav Narayan Verma, Elika Aghanoori, Mohamad Reza Aliani, Michel Kumar, Ashok Fernyhough, Paul Rockman-Greenberg, Cheryl Dhingra, Sanjiv |
author_facet | Sequiera, Glen Lester Srivastava, Abhay Sareen, Niketa Yan, Weiang Alagarsamy, Keshav Narayan Verma, Elika Aghanoori, Mohamad Reza Aliani, Michel Kumar, Ashok Fernyhough, Paul Rockman-Greenberg, Cheryl Dhingra, Sanjiv |
author_sort | Sequiera, Glen Lester |
collection | PubMed |
description | A “Leap-of-Faith” approach is used to treat patients with previously unknown ultrarare pathogenic mutations, often based on evidence from patients having dissimilar but more prevalent mutations. This uncertainty reflects the need to develop personalized prescreening platforms for these patients to assess drug efficacy before considering clinical trial enrollment. In this study, we report an 18-year-old patient with ultrarare Leigh-like syndrome. This patient had previously participated in two clinical trials with unfavorable responses. We established an induced pluripotent stem cell (iPSC)–based platform for this patient, and assessed the efficacy of a panel of drugs. The iPSC platform validated the safety and efficacy of the screened drugs. The efficacy of three of the screened drugs was also investigated in the patient. After 3 years of treatment, the drugs were effective in shifting the metabolic profile of this patient toward healthy control. Therefore, this personalized iPSC-based platform can act as a prescreening tool to help in decision-making with respect to patient’s participation in future clinical trials. |
format | Online Article Text |
id | pubmed-8993122 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | American Association for the Advancement of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-89931222022-04-22 Development of iPSC-based clinical trial selection platform for patients with ultrarare diseases Sequiera, Glen Lester Srivastava, Abhay Sareen, Niketa Yan, Weiang Alagarsamy, Keshav Narayan Verma, Elika Aghanoori, Mohamad Reza Aliani, Michel Kumar, Ashok Fernyhough, Paul Rockman-Greenberg, Cheryl Dhingra, Sanjiv Sci Adv Biomedicine and Life Sciences A “Leap-of-Faith” approach is used to treat patients with previously unknown ultrarare pathogenic mutations, often based on evidence from patients having dissimilar but more prevalent mutations. This uncertainty reflects the need to develop personalized prescreening platforms for these patients to assess drug efficacy before considering clinical trial enrollment. In this study, we report an 18-year-old patient with ultrarare Leigh-like syndrome. This patient had previously participated in two clinical trials with unfavorable responses. We established an induced pluripotent stem cell (iPSC)–based platform for this patient, and assessed the efficacy of a panel of drugs. The iPSC platform validated the safety and efficacy of the screened drugs. The efficacy of three of the screened drugs was also investigated in the patient. After 3 years of treatment, the drugs were effective in shifting the metabolic profile of this patient toward healthy control. Therefore, this personalized iPSC-based platform can act as a prescreening tool to help in decision-making with respect to patient’s participation in future clinical trials. American Association for the Advancement of Science 2022-04-08 /pmc/articles/PMC8993122/ /pubmed/35394834 http://dx.doi.org/10.1126/sciadv.abl4370 Text en Copyright © 2022 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works. Distributed under a Creative Commons Attribution NonCommercial License 4.0 (CC BY-NC). https://creativecommons.org/licenses/by-nc/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial license (https://creativecommons.org/licenses/by-nc/4.0/) , which permits use, distribution, and reproduction in any medium, so long as the resultant use is not for commercial advantage and provided the original work is properly cited. |
spellingShingle | Biomedicine and Life Sciences Sequiera, Glen Lester Srivastava, Abhay Sareen, Niketa Yan, Weiang Alagarsamy, Keshav Narayan Verma, Elika Aghanoori, Mohamad Reza Aliani, Michel Kumar, Ashok Fernyhough, Paul Rockman-Greenberg, Cheryl Dhingra, Sanjiv Development of iPSC-based clinical trial selection platform for patients with ultrarare diseases |
title | Development of iPSC-based clinical trial selection platform for patients with ultrarare diseases |
title_full | Development of iPSC-based clinical trial selection platform for patients with ultrarare diseases |
title_fullStr | Development of iPSC-based clinical trial selection platform for patients with ultrarare diseases |
title_full_unstemmed | Development of iPSC-based clinical trial selection platform for patients with ultrarare diseases |
title_short | Development of iPSC-based clinical trial selection platform for patients with ultrarare diseases |
title_sort | development of ipsc-based clinical trial selection platform for patients with ultrarare diseases |
topic | Biomedicine and Life Sciences |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8993122/ https://www.ncbi.nlm.nih.gov/pubmed/35394834 http://dx.doi.org/10.1126/sciadv.abl4370 |
work_keys_str_mv | AT sequieraglenlester developmentofipscbasedclinicaltrialselectionplatformforpatientswithultrararediseases AT srivastavaabhay developmentofipscbasedclinicaltrialselectionplatformforpatientswithultrararediseases AT sareenniketa developmentofipscbasedclinicaltrialselectionplatformforpatientswithultrararediseases AT yanweiang developmentofipscbasedclinicaltrialselectionplatformforpatientswithultrararediseases AT alagarsamykeshavnarayan developmentofipscbasedclinicaltrialselectionplatformforpatientswithultrararediseases AT vermaelika developmentofipscbasedclinicaltrialselectionplatformforpatientswithultrararediseases AT aghanoorimohamadreza developmentofipscbasedclinicaltrialselectionplatformforpatientswithultrararediseases AT alianimichel developmentofipscbasedclinicaltrialselectionplatformforpatientswithultrararediseases AT kumarashok developmentofipscbasedclinicaltrialselectionplatformforpatientswithultrararediseases AT fernyhoughpaul developmentofipscbasedclinicaltrialselectionplatformforpatientswithultrararediseases AT rockmangreenbergcheryl developmentofipscbasedclinicaltrialselectionplatformforpatientswithultrararediseases AT dhingrasanjiv developmentofipscbasedclinicaltrialselectionplatformforpatientswithultrararediseases |